Crowdfunding & retail investment in biotech

Crowdfunding and retail investment platforms let non-accredited individual investors fund early-stage biotech companies directly, either through conventional equity stakes under securities-crowdfunding exemptions or through blockchain-based tokenized intellectual property (IP-NFTs) issued by decentralized-science (DeSci) organizations. Wefunder, operating under the US Regulation Crowdfunding (Reg CF) exemption, hosted live 2026 raises for companies including Mahzi Therapeutics (gene therapy for Pitt Hopkins Syndrome and related rare neurodevelopmental disorders) and Eliaz Therapeutics (XGal-3, an apheresis device targeting sepsis). StartEngine, which can raise under both Reg CF and the larger Regulation A+ exemption (up to $75 million), has hosted campaigns for Eliaz Therapeutics and Frontier Bio, a developer of lab-grown human tissue models and tissue-engineered vascular grafts. Molecule, based in Switzerland, operates the leading DeSci infrastructure for tokenizing biotech intellectual property as IP-NFTs; its Molecule Protocol V2, launched in 2025, integrates these IP-backed tokens with traditional corporate equity as a new “real-world asset” class, and its Molecule Labs interface (launched mid-2025) gives researchers a data hub for managing tokenized IP directly. VitaDAO, a decentralized autonomous organization funding longevity research through onchain governance, has funded gene-therapy programs such as Artan Bio and pursues its own Healthspan XPRIZE research plan. In the UK, Crowdcube hosted a 2026 raise for Equisera, whose RiPR supercritical water-reforming technology converts biogenic and mixed waste into biomethane, hydrogen, captured CO2 and biochar. Republic, a global crowdfunding platform with more than 3 million investors since 2016, partnered with healthcare-focused equity-crowdfunding platform RedCrow to expand its healthcare and biotech investment offerings.

The key directions of crowdfunding and retail investment in biotech are:

1. Regulation Crowdfunding (Reg CF) equity raises: US biotech startups selling equity stakes directly to non-accredited retail investors under SEC exemptions, typically with minimum investments as low as $100.
2. Regulation A+ and larger retail raises: a bigger US exemption (up to $75 million) allowing more mature biotech companies to raise larger rounds from the retail public with lighter disclosure than a full IPO.
3. Decentralized science (DeSci) and IP-NFTs: tokenizing a lab’s intellectual property rights as blockchain assets, letting a DAO or individual token holders fund early research in exchange for a share of future IP value.
4. Cross-border European crowdfunding: platforms operating under the EU’s unified European Crowdfunding Service Providers (ECSP) license, letting a single campaign legally raise from retail investors across all EU member states.

Sectoral value chain#

[Startup listing & legal/financial audit] ──> [Campaign marketing & community building] ──> [Equity sale / IP-NFT minting]
                                                                                                        │
                                                                                          (Escrow & investor compliance checks)
                                                                                                        │
     [Clinical/R&D progress & investor reporting] <─── [Capital deployment into lab operations] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• IP-NFT tokenization: converting a lab’s intellectual-property rights (data-sharing agreements, licenses) into blockchain tokens (commonly ERC-1155) that a DAO or individual can buy, sell or hold as a claim on future IP value.
• Reg CF/Reg A+ smart-contract escrow: automated systems that hold investor funds until a campaign’s minimum funding target (“soft cap”) is met, distributing equity or refunding 100% of funds if the target is missed.
• DAO token governance: token-holder voting mechanisms that let a decentralized community decide which research projects a DeSci organization funds, in effect crowdsourcing grant review.

The biotech crowdfunding and DeSci stack pairs securities-compliance technology with blockchain infrastructure for tokenizing early-stage research assets:

1. IP-NFT tokenization:
   • A lab’s intellectual-property rights and data-sharing agreements are converted into blockchain tokens (commonly ERC-1155), letting a DAO or individual investor hold a claim on future licensing value without a traditional equity structure.
2. Reg CF/Reg A+ compliant escrow automation:
   • Smart-contract or platform-managed escrow systems hold investor funds until a campaign’s minimum funding target is met, automatically distributing shares or refunding all capital if the target is missed, removing manual reconciliation risk.
3. DAO token governance for grant allocation:
   • Token-holder voting mechanisms let a distributed community of retail backers decide which research proposals a DeSci organization funds, replacing a centralized grant committee with crowdsourced peer review.